Barinthus Biotherapeutics plc annual return on equity
2021
2022
2023
2024
2025
Barinthus Biotherapeutics plc Return on Equity (ROE) Growth & History (BRNS)
Barinthus Biotherapeutics plc's return on equity was −65.05% for fiscal 2025.
View full Barinthus Biotherapeutics plc company overviewBarinthus Biotherapeutics plc annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −65.05% | −26.49 pp |
| 2024 | 2024-12-31 | −38.56% | −4.41 pp |
| 2023 | 2023-12-31 | −34.14% | −36.30 pp |
| 2022 | 2022-12-31 | 2.16% | +49.43 pp |
| 2021 | 2021-12-31 | −47.27% | — |
Barinthus Biotherapeutics plc quarterly return on equity
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −17.14% | +2.25 pp |
| Q1 2026 | 2026-03-31 | −7.87% | +8.14 pp |
| Q4 2025 | 2025-12-31 | −13.98% | +0.22 pp |
| Q3 2025 | 2025-09-30 | −15.59% | −10.45 pp |
| Q2 2025 | 2025-06-30 | −19.39% | −9.08 pp |
| Q1 2025 | 2025-03-31 | −16.01% | −7.37 pp |
| Q4 2024 | 2024-12-31 | −14.20% | −5.15 pp |
| Q3 2024 | 2024-09-30 | −5.14% | +1.68 pp |
| Q2 2024 | 2024-06-30 | −10.31% | +0.26 pp |
| Q1 2024 | 2024-03-31 | −8.64% | −1.00 pp |
| Q4 2023 | 2023-12-31 | −9.05% | −0.34 pp |
| Q3 2023 | 2023-09-30 | −6.82% | −10.13 pp |
| Q2 2023 | 2023-06-30 | −10.57% | −16.75 pp |
| Q1 2023 | 2023-03-31 | −7.64% | −8.66 pp |
| Q4 2022 | 2022-12-31 | −8.71% | −2.60 pp |
| Q3 2022 | 2022-09-30 | 3.31% | +5.16 pp |
| Q2 2022 | 2022-06-30 | 6.18% | +22.35 pp |
| Q1 2022 | 2022-03-31 | 1.03% | — |
| Q4 2021 | 2021-12-31 | −6.11% | — |
| Q3 2021 | 2021-09-30 | −1.85% | — |
| Q2 2021 | 2021-06-30 | −16.16% | — |
Barinthus Biotherapeutics plc return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Barinthus Biotherapeutics plc's return on equity decreased from −47.27% to −65.05%, a change of −17.78 percentage points. The latest reported quarter, Q2 2026, shows −17.14%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Barinthus Biotherapeutics plc source filings ↗